Karachi, Abbott Laboratories (Pakistan) Limited has revealed plans for a significant virtual meeting of its Board of Directors on August 28, 2023. The primary objective of this meeting is to deliberate and assess the Half Yearly Accounts for the period ending June 30th, 2023. The meeting is expected to facilitate strategic discussions regarding the company's financial performance and future direction.

By opting for a virtual format, the company aims to ensure efficient communication and decision-making among its Directors while adapting to the evolving dynamics of the business landscape.

Concurrently, Abbott Laboratories (Pakistan) has announced the initiation of a "Close Period" that extends from August 21, 2023, to August 28, 2023. This measure aligns with Clause 5.6.9 (b) of the PSX (Pakistan Stock Exchange) Regulations, and during this period, no Director, CEO, or Executive is permitted to engage in any form of share dealing related to the company. This decision is aimed at upholding transparency and safeguarding the interests of all stakeholders.

The declaration of a Close Period ensures that no insider trading or manipulation can occur during a crucial period when significant financial information is being discussed and reviewed. This practice promotes a level playing field for all investors.

As Abbott Laboratories (Pakistan) prepares for its virtual Board meeting and adheres to the Close Period, investors, shareholders, and market observers will be keenly monitoring any decisions and outcomes stemming from the meeting. The company's financial performance, strategic outlook, and potential declarations will be subjects of considerable interest and scrutiny.